

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Synthesis and In Vitro Antiviral Activity of Some Symmetrical Phosphoramidate Dimers of AZT

I. Kers<sup>a</sup>; J-L. Girardet<sup>b</sup>; G. Gosselin<sup>b</sup>; C. Perigaud<sup>b</sup>; J-L. Imbach<sup>b</sup>; J. Stawinski<sup>a</sup>

<sup>a</sup> Department of Organic Chemistry, Arrhenius Laboratory, Stockholm University, Stockholm, Sweden

<sup>b</sup> Laboratoire de Chimie Bioorganique, UMR CNRS 5625, Universite de Montpellier II, Montpellier Cedex 5, France

**To cite this Article** Kers, I. , Girardet, J-L. , Gosselin, G. , Perigaud, C. , Imbach, J-L. and Stawinski, J.(1999) 'Synthesis and In Vitro Antiviral Activity of Some Symmetrical Phosphoramidate Dimers of AZT', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 4, 993 – 994

**To link to this Article:** DOI: 10.1080/15257779908041626

**URL:** <http://dx.doi.org/10.1080/15257779908041626>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SYNTHESIS AND *IN VITRO* ANTIVIRAL ACTIVITY OF SOME SYMMETRICAL PHOSPHORAMIDATE DIMERS OF AZT

I. Kers, J.-L. Girardet<sup>a</sup>, G. Gosselin<sup>a\*</sup>, C. Perigaud<sup>a</sup>,  
J.-L. Imbach<sup>a</sup> and J. Stawinski\*

Department of Organic Chemistry, Arrhenius Laboratory, Stockholm University,  
S-106 91 Stockholm, Sweden; <sup>a</sup>Laboratoire de Chimie Bioorganique, UMR CNRS 5625,  
Universite de Montpellier II, 34095 Montpellier, Cedex 5, France

**ABSTRACT:** The synthesis of some symmetrical phosphoramidate dimers of AZT is presented. The synthetic scheme includes the formation of the symmetrical H-phosphonate diester of AZT, followed by its conversion to several dinucleoside phosphoramidate analogues. The compounds were evaluated for their anti-retroviral activity.

We have synthesized different phosphoramidates **1** (Fig. 1) as potential antiviral agents. These compounds were designed with the aim to act as prodrugs for both 3'-azido-3'-deoxythymidine (AZT) and its 5'-phosphorylated derivative (AZTMP)<sup>1</sup>. The synthetic





Fig. 1

strategy used was based on H-phosphonate chemistry<sup>2</sup> and consisted of two steps: (i) the formation of the symmetrical H-phosphonate diester of AZT and (ii) its conversion into the desired phosphoramidates *via* oxidative coupling with a corresponding amine (Scheme 1). The symmetrical H-phosphonate diester **3** had been earlier prepared from phosphonic acid using pivaloyl chloride as a condensing agent<sup>3</sup>. To develop a more convenient procedure

for the synthesis of **3** we studied the dicyclohexylcarbodiimide (DCC) mediated condensation of phosphonic acid with AZT. We found that symmetrical H-phosphonate diester **3** could be produced practically quantitatively ( $^{31}\text{P}$  NMR) using pyridinium phosphonate **2** (1 equiv.), AZT (2 equiv.) and DCC (3 equiv.) in pyridine. The condensation was complete within one hour. The presence of pyridinium hydrochloride



(2 equiv.) was necessary to ensure reproducible results. The produced symmetrical H-phosphonate **3** could be used without purification for the subsequent oxidative couplings (Scheme 1) to afford target compounds **1** in 80-90% yield (after silica gel column purification).

The synthesized compounds were evaluated for their anti-retroviral activity in different cell cultures. They were found to be active in cells expressing thymidine kinase (comparable to AZT), but inactive in CEM/TK<sup>-</sup> cells ( $\text{IC}_{50} > 10\ \mu\text{M}$ ), thus suggesting that these compounds are not able to deliver AZTMP inside the cells.

#### Acknowledgements

Financial support from the Swedish Natural Science Research Council, CNRS and INSERM, France, is gratefully acknowledged.

#### REFERENCES

1. Perigaud, C.; Gosselin, G.; Imbach, J.-L. *Nucleosides Nucleotides* **1992**, *11*, 904-954.
2. Stawinski, J. In *Handbook of Organophosphorus Chemistry*; R. Engel, Ed.; Marcel Dekker: New York, 1992; pp 377-434.
3. Gosselin, G.; Périgaud, C.; Lefebvre, I.; Pompon, A.; Aubertin, A.-M.; Kirn, A.; Szabó, T.; Stawinski, J.; Imbach, J.-L. *Antiviral Res.* **1993**, *22*, 143-153.